Literature DB >> 26071654

Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans.

Nirav K Desai1, Esther M Ooi2, Paul D Mitchell3, Jeremy Furtado4, Frank M Sacks5.   

Abstract

OBJECTIVE: To characterize human triglyceride-rich lipoproteins (TRL) with and without apoA-II and to study their metabolism in vivo.
METHODS: Plasma from 11 participants on a controlled diet given a bolus infusion of [D5]l-phenylalanine to label apoB was combined into four pools and applied to anti-apoA-II immunoaffinity columns. Fractions with and without apoA-II were separated into VLDL and IDL by ultracentrifugation; lipids and apolipoproteins were measured. For kinetic measurements, apoB was isolated and hydrolyzed to the constituent amino acids. Tracer enrichment was measured by GCMS. Metabolic rates were determined by SAAM-II.
RESULTS: VLDL and IDL with apoA-II comprised 7% and 9% of total VLDL and IDL apoB respectively. VLDL with apoA-II was enriched in apoC-III, apoE, and cholesterol compared to VLDL without apoA-II. Mean apoB FCR of VLDL with apoA-II was significantly lower than for VLDL without apoA-II (2.80 ± 0.96 pools/day v.s. 5.09 ± 1.69 pools/day, P = 0.009). A higher percentage of VLDL with apoA-II was converted to IDL than was cleared from circulation, compared to VLDL without apoA-II (96 ± 8% vs. 45 ± 22%; P = 0.007). The rate constants for conversion of VLDL to IDL were similar for VLDL with and without apoA-II. Thus, a very low rate constant for clearance accounted for the lower FCR of VLDL with apoA-II.
CONCLUSION: VLDL with apoA-II represents a small pool of VLDL particles that has a slow FCR and is predominantly converted to IDL rather than cleared from the circulation.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apolipoprotein A-II; Lipid metabolism; Triglyceride rich lipoproteins; VLDL

Mesh:

Substances:

Year:  2015        PMID: 26071654      PMCID: PMC4509984          DOI: 10.1016/j.atherosclerosis.2015.05.013

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction.

Authors:  K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1978-09-10       Impact factor: 5.157

Review 2.  Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans.

Authors:  P Hugh R Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2006-05-25       Impact factor: 5.922

3.  Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.

Authors:  J C Escolà-Gil; J Julve; A Marzal-Casacuberta; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

4.  Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet.

Authors:  J Julve; J C Escolà-Gil; A Marzal-Casacuberta; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  Biochim Biophys Acta       Date:  2000-11-15

5.  Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.

Authors:  C S Wang; P Alaupovic; R E Gregg; H B Brewer
Journal:  Biochim Biophys Acta       Date:  1987-07-13

6.  Plasma triglyceride metabolism in thyroid disease.

Authors:  E A Nikkilä; M Kekki
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

7.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

8.  The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay.

Authors:  M C Cheung; J J Albers
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

9.  Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Katsunori Ikewaki; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

10.  Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.

Authors:  Carlos O Mendivil; Chunyu Zheng; Jeremy Furtado; Julian Lel; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

View more
  1 in total

1.  LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.

Authors:  John D Bagdade; Bernd Jilma; Lisa C Hudgins; Petar Alaupovic; Carrie E McCurdy
Journal:  Lipids Health Dis       Date:  2018-05-28       Impact factor: 3.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.